Clinical trials: HIV Seronegativity
HIV Infections
Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
The purpose of this study is to see if the vaccines tested are safe when given alone and when given together, and how the immune system responds to the vaccines.
- Trial name
- NCT00007332
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- Where
- 17 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa
The purpose of this study is to see if different doses of an experimental HIV vaccine are safe and to study how the immune system responds to the vaccine. The vaccine will be tested in healthy, HIV uninfected volunteers.
- Trial name
- NCT00063778
- Testing
- AVX101
- Where
- 7 sites in United States, South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
HIV Infections
Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
The purpose of the study is to determine the safety of and immune response to the investigational HIV vaccine, EP HIV-1090, in HIV uninfected adults.
- Trial name
- NCT00141024
- Testing
- EP HIV-1043, EP HIV-1090
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Sexually Transmitted Disease
Effect of HIV/STD Risk Reduction Program on South African Adolescents
This study will evaluate the effect of an HIV/STD risk-reduction program on the sexual behavior of South African adolescents.
- Trial name
- NCT00559403
- Testing
- HIV/STD Risk-Reduction, Health Promotion
- Volunteers
- 1,057 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV Infections, Acquired Immune Deficiency Syndrome
Reactogenicity and Immunogenicity of Vaginal CNgp140
To determine the local (cervico-vaginal) and systemic (whole body) safety of vaginal immunisation with CN54gp140 glycoprotein administered 9 times over a 3 week period.
- Trial name
- SG06RS02 (NCT00637962)
- Testing
- HIV glycoprotein CN54gp140 (vaccine), Carbopol 974
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
HIV Infections
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose
To determine the safety of and immune response to vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) at a dose of 200 mcg in human volunteers; to evaluate duration of antibody response and its relationship to the…
- Trial name
- NCT00001056
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Development of a New HIV Vaccine
The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore the vaccine cannot itself cause HIV or…
- Trial name
- NCT00051922
- Testing
- PolyEnv1
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
To evaluate the safety, tolerability and immunogenicity in humans of the APL-400-047 vaccine when administered intramuscularly by needle and syringe at 1 of 3 doses or by Biojector at the intermediate dose.
- Trial name
- NCT00001088
- Testing
- APL 400-047, Bupivacaine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir
The main purpose of this study is to examine the effect of tipranavir combined with ritonavir, medications for the treatment of HIV-infection, on buprenorphine/naloxone (BUP) in people who have been receiving the same dose of…
- Trial name
- BUTI (NCT00486330)
- Testing
- Buprenorphine, Tipranavir and ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV Infections, HIV Seronegativity
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection.
- Trial name
- NCT00006298
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Sexually Transmitted Diseases
Maintaining HIV Prevention Gains in Female Adolescents
In this study, an intervention is tested that is designed to reduced risky sexual behaviors in adolescent females. Study design: randomized, controlled study participants: 640 girls aged 15-19 years old length of follow-up: 1…
- Trial name
- NCT00161343
- Testing
- Health Improvement Project for Teens on HIV Prevention
- Where
- United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- University of Rochester
HIV Infections
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it.
- Trial name
- NCT00076063
- Testing
- ALVAC-HIV (vCP1452), LIPO-5
- Where
- 11 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
Carotid Artery Thickness in HIV Infected and Uninfected Adults
The intima-media thickness (IMT) test is a low cost, non-invasive way to measure the thickness of the carotid artery (the large artery in the neck).
- Conditions
- HIV Infections, HIV Seronegativity, Atherosclerosis
- Trial name
- NCT00007319
- Where
- 10 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Opioid-Related Disorders
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently the major mode of transmission of HIV in many countries.
- Trial name
- NCT00270257
- Testing
- Buprenorphine/Naloxone
- Where
- 4 sites in China, Thailand
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Prevention, HIV Infections
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
To date, the majority of microbicide research has focused on the assessment of the safety and effectiveness of vaginal microbicides used for the prevention of HIV transmission via the vaginal compartment.
- Trial name
- RMP02-MTN006 (NCT00984971)
- Testing
- Tenofovir, Open label tenofovir tablet
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- CONRAD
HIV Infections
Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines
The purpose of this study is to determine the safety and immune system response to the TBC-3B HIV vaccine when it is injected either into the groin area or into the arm.
- Trial name
- NCT00056745
- Testing
- TBC-3B
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns
The purpose of this study is to see if nevirapine (NVP) or zidovudine (AZT), given to mothers during labor and delivery and to their babies during the first week of life, can reduce the rate of mothers passing HIV to their…
- Trial name
- NCT00006396
- Testing
- Nevirapine, Zidovudine
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery
A new approach to HIV prevention currently being studied includes the use of topical microbicides, substances that kill microbes.
- Trial name
- NCT00540605
- Testing
- Tenofovir 1% vaginal gel
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa
The development of a safe and effective vaccine is the best strategy for preventing the spread of HIV-1. The purpose of this study is to determine the safety and effectiveness of and immune responses to an HIV vaccine regimen in…
- Trial name
- NCT00498056
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand
The primary goals of this study are to assess the safety and efficacy of daily tenofovir to prevent parenteral HIV infection among injection drug users (IDUs).
- Trial name
- NCT00119106
- Testing
- Tenofovir disoproxil
- Where
- Thailand
- Volunteers
- 2,413 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention